v3.26.1
Note 10 - Stockholders' Equity (Details Textual)
 1 Months Ended 3 Months Ended 9 Months Ended
Oct. 22, 2025
USD ($)
$ / shares
Oct. 05, 2025
USD ($)
$ / shares
Sep. 30, 2025
USD ($)
$ / shares
shares
Jul. 29, 2025
USD ($)
$ / shares
Jun. 26, 2025
USD ($)
Feb. 28, 2025
USD ($)
$ / shares
shares
Sep. 30, 2025
USD ($)
$ / shares
shares
Sep. 30, 2024
USD ($)
Sep. 30, 2025
USD ($)
$ / shares
shares
Sep. 30, 2024
USD ($)
Sep. 29, 2025
$ / shares
Aug. 14, 2025
USD ($)
$ / shares
Jun. 25, 2025
USD ($)
May 14, 2025
USD ($)
Mar. 07, 2025
shares
Dec. 31, 2024
$ / shares
shares
Preferred Stock, Shares Outstanding (in shares) | shares                               0
Preferred Stock, Shares Authorized (in shares) | shares                             25,000,000  
Common Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares     $ 0.0005       $ 0.0005   $ 0.0005             $ 0.0005
Share Price (in dollars per share) | $ / shares                     $ 1.32          
Proceeds from Issuance of Debt                 $ 3,000,000 $ 0            
Gain (Loss) on Extinguishment of Debt             $ (652,000) $ 0 (652,000) $ 0            
Equity Line Investor Purchase Agreement [Member]                                
Amount of Volume Weighted Average Price of the Common Stock         $ 3,000,000                      
Equity Line Investor Purchase Agreement [Member]                                
Equity Offering, Maximum Offering Amount                           $ 20,000,000    
Percentage of Lowest Daily Volume Weighted Average Price         40.00%                 97.00%    
Equity Offering Stock Price Trigger         100.00%                      
Dollar-based limitation on the Number of Equity Line Securities         $ 3,000,000               $ 2,000,000      
BP Peptides, LLC [Member]                                
Debt Instrument, Face Amount     $ 847,920       847,920   847,920              
Brookstone Partners Acquisition XXI Corporation [Member]                                
Debt Instrument, Face Amount     $ 1,089,222       1,089,222   1,089,222              
Institutional Investor [Member] | Senior Secured Convertible Notes [Member]                                
Debt Instrument, Face Amount       $ 3,272,966               $ 1,363,736        
Common Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares       $ 0.0005                        
Debt Agreement, AuthoMaximum Borrowing Capacity       $ 10,909,885                        
Debt Instrument, Original Issue Discount, Rate       8.34                        
Debt Instrument, Convertible, Conversion Price (in dollars per share) | $ / shares       $ 1.72               $ 1        
Proceeds from Issuance of Debt       $ 3,000,000                        
Debt Instrument, Interest Rate, Stated Percentage       7.00%                        
Debt Instrument, Fair Value Disclosure                       $ 1,759,219        
Gain (Loss) on Extinguishment of Debt             $ (652,161)   $ (652,161)              
Institutional Investor [Member] | Senior Secured Convertible Notes [Member] | Subsequent Event [Member]                                
Debt Instrument, Face Amount $ 3,545,712                              
Common Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares $ 0.0005                              
Debt Instrument, Convertible, Conversion Price (in dollars per share) | $ / shares $ 1.1 $ 1                            
Proceeds from Issuance of Debt $ 3,250,000                              
Debt Instrument, Interest Rate, Stated Percentage 7.00%                              
Gain (Loss) on Extinguishment of Debt   $ 845,000                            
Series B Preferred Stock [Member]                                
Preferred Stock, Shares Authorized (in shares) | shares     2,000,000       2,000,000   2,000,000             0
Preferred Stock, No Par Value (in dollars per share) | $ / shares     $ 0       $ 0   $ 0             $ 0
Common Stock, Closing Price Requirement on the Date of Conversion (in dollars per share) | $ / shares           $ 40                    
Preferred Stock, Percentage of Outstanding Stock Required for Appointments to Board           50.00%                    
Series B Preferred Stock [Member] | Nectarine Management LLC [Member]                                
Stock Issued During Period, Shares, New Issues (in shares) | shares           985,063                    
Proceeds from Issuance of Convertible Preferred Stock           $ 30,000                    
Series Z Preferred Stock [Member]                                
Preferred Stock, Shares Authorized (in shares) | shares     3,500,000       3,500,000   3,500,000             0
Preferred Stock, No Par Value (in dollars per share) | $ / shares     $ 0       $ 0   $ 0             $ 0
Ownership Percentage of Voting Stocks     50       50   50              
Preferred Stock, Dividend Rate, Percentage     8.00%                          
Preferred Stock, Dividend Rate, Per-Dollar-Amount (in dollars per share) | $ / shares     $ 1.32                          
Series Z Preferred Stock [Member] | BP Peptides, LLC [Member] | Conversion of Note Payable to BP Peptides, LLC. to Series Z Preferred Stock [Member]                                
Debt Conversion, Converted Instrument, Shares Issued (in shares) | shares     642,364                          
Series Z Preferred Stock [Member] | Brookstone Partners Acquisition XXI Corporation [Member] | Conversion of Note Payable to BP Peptides, LLC. to Series Z Preferred Stock [Member]                                
Debt Conversion, Converted Instrument, Shares Issued (in shares) | shares     825,168